taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas.
Company profile
Ticker
TSHA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
843199512
TSHA stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
18 Apr 24
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
S-8
Registration of securities for employees
19 Mar 24
8-K
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
10 Jan 24
8-K
Departure of Directors or Certain Officers
20 Dec 23
S-8
Registration of securities for employees
20 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
15 Nov 23
Transcripts
TSHA
Earnings call transcript
2023 Q3
14 Nov 23
TSHA
Earnings call transcript
2023 Q2
14 Aug 23
TSHA
Earnings call transcript
2023 Q1
11 May 23
TSHA
Earnings call transcript
2022 Q4
28 Mar 23
TSHA
Earnings call transcript
2022 Q3
13 Nov 22
TSHA
Earnings call transcript
2022 Q2
13 Aug 22
TSHA
Earnings call transcript
2022 Q1
16 May 22
TSHA
Earnings call transcript
2021 Q4
31 Mar 22
TSHA
Earnings call transcript
2021 Q3
10 Nov 21
TSHA
Earnings call transcript
2021 Q2
16 Aug 21
Latest ownership filings
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
TCG Crossover GP I, LLC
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Kamran Alam
6 Feb 24
4
Kamran Alam
4 Jan 24
4
Sukumar Nagendran
4 Jan 24
4
Sean P. Nolan
4 Jan 24
4
Kamran Alam
18 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 166.92 mm | 166.92 mm | 166.92 mm | 166.92 mm | 166.92 mm | 166.92 mm |
Cash burn (monthly) | (no burn) | (no burn) | 5.42 mm | 9.18 mm | 5.98 mm | 3.52 mm |
Cash used (since last report) | n/a | n/a | 39.40 mm | 66.77 mm | 43.51 mm | 25.57 mm |
Cash remaining | n/a | n/a | 127.52 mm | 100.15 mm | 123.40 mm | 141.35 mm |
Runway (months of cash) | n/a | n/a | 23.5 | 10.9 | 20.6 | 40.2 |
Institutional ownership, Q4 2023
30.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 2 |
Closed positions | 60 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 300.22 mm |
Total shares | 56.83 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Paul B Manning | 16.47 mm | $31.78 mm |
Venrock Healthcare Capital Partners III | 14.44 mm | $27.88 mm |
TCG Crossover GP I | 11.11 mm | $21.44 mm |
ALPMF Astellas Pharma | 7.27 mm | $14.02 mm |
Audentes Therapeutics | 7.27 mm | $10.61 mm |
Session R.A. II | 141.09 k | $0.00 |
Dynamic Advisor Solutions | 45.00 k | $80.10 mm |
Redwood Wealth Management | 42.60 k | $75.40 mm |
China Universal Asset Management | 21.62 k | $38.00 k |
Camelot Portfolios | 11.00 k | $19.47 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Feb 24 | Kamran Alam | Common Stock | Payment of exercise | Dispose F | No | No | 1.51 | 1,288 | 1.94 k | 840,937 |
2 Jan 24 | Nolan Sean P. | Common Stock | Grant | Acquire A | No | No | 0 | 1,184,688 | 0.00 | 1,185,858 |
2 Jan 24 | Nolan Sean P. | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.71 | 1,184,688 | 2.03 mm | 1,184,688 |
2 Jan 24 | Nagendran Sukumar | Common Stock | Grant | Acquire A | No | No | 0 | 863,617 | 0.00 | 897,843 |
2 Jan 24 | Nagendran Sukumar | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.71 | 863,617 | 1.48 mm | 863,617 |
2 Jan 24 | Kamran Alam | Common Stock | Grant | Acquire A | No | No | 0 | 590,413 | 0.00 | 842,225 |
2 Jan 24 | Kamran Alam | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.71 | 590,413 | 1.01 mm | 590,413 |
14 Dec 23 | Nolan Sean P. | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.6989 | 466,550 | 326.07 k | 466,550 |
News
Needham Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
2 May 24
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy Designation Granted By U.S. FDA For TSHA-102 In Rett Syndrome
2 May 24
Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target
30 Apr 24
Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target
18 Apr 24
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
12 Apr 24
Press releases
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
7 May 24
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3 May 24
Thinking about buying stock in Archer Aviation, Lantern Pharma, Taysha Gene Therapies, Pagaya Technologies, or Blink Charging?
20 Mar 24
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
14 Mar 24
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1 Mar 24